Core Viewpoint - The Hong Kong pharmaceutical sector, particularly the innovative drug segment, is experiencing a significant surge, driven by recent high-profile collaborations and a shift towards international competitiveness among Chinese pharmaceutical companies [1][11]. Group 1: Innovative Drug Collaborations - Pfizer's collaboration with 3SBio involves a record-breaking upfront payment of $1.25 billion and potential milestone payments of up to $4.8 billion, boosting confidence in the international capabilities of Chinese innovative drugs [1][5]. - Other notable collaborations include a $200 million upfront payment from United Pharmaceuticals to Novo Nordisk and a $175 million upfront payment from Hengrui Medicine to Merck, indicating a trend of increasing international partnerships [5]. - The average price-to-earnings (P/E) ratio for the Hong Kong pharmaceutical sector is currently at 15 times, significantly lower than the 24 times for both A-shares and U.S. stocks, suggesting a strong value proposition for investors [7]. Group 2: Technological Advancements - Chinese pharmaceutical companies are transitioning from "generic followers" to "innovation leaders," with R&D costs being only one-third of those in the U.S. and clinical trial durations reduced by 30% [1][2]. - Companies like Decipher Biosciences and Kintor Pharmaceutical are leveraging AI to enhance drug development efficiency, with significant improvements in response rates for clinical trials [1][2]. Group 3: Upcoming ASCO Conference - The 2025 ASCO Annual Meeting, scheduled for May 30 to June 3, will feature over 500 oral presentations and 2,700 poster presentations, with 71 original research projects from Chinese scholars, potentially leading to further stock price increases for involved companies [3][4]. Group 4: Market Dynamics and Valuation - The Hong Kong healthcare index has seen a nearly 20% increase prior to the announcement of 3SBio's contract, with a subsequent 4% rise following the news, indicating strong market interest [1]. - The current valuation levels are at historical lows, with some stocks trading below their net asset values, providing a significant safety margin for investors [7][8]. Group 5: Policy and Market Support - Recent policy changes have reduced pressures from centralized procurement, allowing innovative drugs to enter insurance coverage more rapidly, which is expected to enhance profitability for companies with genuine innovation capabilities [9]. - The government's support for biopharmaceuticals and the anticipated release of a new innovative drug directory could unlock over 300 billion yuan in market space, benefiting leading therapies like BeiGene's PD-1 inhibitors [9]. Group 6: Investment Trends - There has been a notable increase in capital inflow into the Hong Kong pharmaceutical sector, with net inflows into innovative drug ETFs exceeding 5 billion yuan since the second quarter [10]. - Active pharmaceutical funds are increasing their holdings in Hong Kong stocks, reflecting a growing confidence in the sector's potential for recovery and growth [10][11].

陈茂波在5月18日发布的文章中指出，今年以来，港股反复向好。恒生指数周五（5月16日）收报23345 点，累计升幅约16%，跑赢其他主要市场。大市交投亦有所增加，以4月份为例，平均每日成交超过 2,700亿元，较去年同期上升1.4倍。 在市场看来，在国内利率进入下行周期、资产配置重心逐步从增长转向回报的背景下，红利资产受到市 场较高关注。国信证券研报指出，尤其是在港股市场整体估值处于历史低位、企业派息意愿持续增强、 政策支持资本市场长期资金入市的环境中，港股通红利指数逐渐成为投资者配置高现金流、低波动品种 的重要工具。 财通证券研报认为，今年以来A股龙头公司赴港上市，受包括外资在内的投资者青睐，宁德时代当前H 股较A股溢价约10%，反映国内优质资产正受到全球投资者认可。后续有待在港交所上市的A股公司可 能受港股带动，享受估值修复红利。（闻辉） 【环球网财经综合报道】5月25日，香港财政司司长陈茂波发文透露，今年以来，香港新股集资额超过 760亿港元，较去年同期增加超过七倍，并已达到去年全年新股集资总额接近九成。 过去一周香港新股市场迎来了今年来全球最大宗的新股上市。5月20日，宁德时代在港交所上市。陈茂 波此 ...

Investment Rating - The industry rating is "Recommended" [4] Core Insights - The report highlights that Tmall and Taobao platforms experienced negative growth in various categories in April 2025, with the highest growth seen in Jin Hong Group [7] - Deckers reported a 16.3% revenue increase to $4.986 billion for FY2025, with operating profit rising by 27.1% to $1.179 billion, and a gross margin increase of 2.3 percentage points to 57.9% [15] - VF Corporation's revenue decreased by 4% to $9.504 billion for FY2025, with a net loss of $190 million, although the loss narrowed compared to the previous year [16] Summary by Sections Company Performance - Tmall and Taobao platforms saw negative growth across categories in April 2025, with Jin Hong Group showing the highest growth [7] - Deckers' FY2025 revenue grew by 16.3% to $4.986 billion, with operating profit increasing by 27.1% to $1.179 billion, and a gross margin of 57.9% [15] - VF Corporation's revenue fell by 4% to $9.504 billion, with a net loss of $190 million, but the loss was less than the previous year [16] - Amphenol's Q1 2025 revenue was $1.473 billion, with a net profit increase of 2539.22% [17] Market Trends - The textile and apparel industry saw a decline in stock performance, with the SW textile and apparel sector down 1.31% [20] - The cotton price index in China increased by 0.29% as of May 23, 2025, while the medium import cotton price index rose by 1.06% [30] - The USDA forecasts a 2.7% decrease in global cotton production for the 2025/2026 season [40] Investment Recommendations - The report suggests short-term recommendations for companies with high U.S. revenue exposure and significant prior declines, while mid-term recommendations focus on companies with high overseas exposure [18][19] - Long-term recommendations include companies with growth potential, such as Zhejiang Natural and Kai Run Co., which have favorable market positions [19]

Group 1: Market Overview - A-share market showed increased structural differentiation on May 22, with high-position thematic stocks retreating and the North China 50 Index dropping over 6% [2] - The Shanghai Composite Index closed down 0.22% at 3380.19 points, while the Shenzhen Component Index fell 0.72% to 10219.62 points, and the ChiNext Index decreased by 0.96% to 2045.57 points [2] Group 2: Bank Sector Performance - Bank stocks rose against the market trend, with several banks like Pudong Development Bank, Jiangsu Bank, and Chengdu Bank reaching historical highs, while others like Qingdao Bank and CITIC Bank increased by over 2% [3] - Major state-owned banks and several others lowered RMB deposit rates on May 20, which is expected to positively impact net interest margins and allow banks to increase government bond allocations to support the real economy [3][4] - The valuation recovery logic driven by bank stock dividends is expected to continue, with limited downward pressure on net interest margins and stable performance anticipated [3] Group 3: High-Position Stock Dynamics - High-position stocks have become a market focus amid fluctuations, with stocks like Nanjing Port experiencing significant volatility, including a 7.21% increase after a drop [4] - Over 80 stocks have doubled in price this year, primarily in sectors like restructuring, price increases, robotics, AI, and new consumption, although many of these are small-cap stocks with poor performance [4][5] Group 4: Valuation Concerns - Some doubling stocks, such as Zhongyida, have been flagged for high valuations despite significant price increases, with a cumulative rise of 252.61% while the company remains in a loss position [5] - The market is expected to continue a volatile trend with low trading volumes, and structural opportunities may arise in sectors like export industry chains, domestic demand expansion, high dividend yields, and mergers and acquisitions [5]

作者 | 周智宇 编辑 | 张晓玲 二季度市场会"退一步进两步"，若三季度贸易谈判取得实质性进展，港股有望突破当前区间。摩根大通 首席亚洲及中国股票策略师刘鸣镝在5月21日的"摩根大通全球中国峰会媒体见面会"上，就接下来的市 场走势给出如是判断。 短期来看，4月初贸易摩擦升温导致港股大幅回调，但随后市场逐步消化利空并反弹，当前处于区间震 荡。 此外，她也认为国资委及证监会对兼并重组的政策支持，有望推动材料、工业等板块的供给侧改革，这 一主题类似2016年的供给侧改革，但执行难度更大。对投资者而言，A股的机会在于从"估值博弈"转 向"盈利增长"，关注具备内生扩张或并购潜力的企业，而非单纯依赖流动性驱动的中小盘标的。 刘鸣镝特别强调港股的独特优势。港股对上市公司业绩敏感度高，盈利增长明确的企业易获资金认可， 流动性虽不及A股但估值体系更趋理性；随着中概股回归及内地企业赴港上市，港股成为连接内地与全 球资本的桥梁。南下资金（港股通）交易量占比已达20%-25%，边际定价权显著提升，央行外管对港股 的政策倾斜进一步强化其地位。 此外，港股红利股对应美元资产收益，相比内地国债利率更具吸引力，成为稳健型资金的优选。 从全 ...

Group 1 - The core viewpoint of the news highlights the positive performance of the Hong Kong Stock Connect Technology ETF (513860), which rose by 1.29% to a price of 0.71 yuan, with a trading volume of 20.75 million yuan as of May 20, 2025 [1] - Notable constituent stocks include 3SBio, which increased by over 29%, and other companies like Innovent Biologics, Zai Lab, and Li Auto, which saw gains of over 4% [1] - On May 19, 2025, 3SBio entered into an exclusive licensing agreement with Pfizer, granting Pfizer global rights to the PD-1/VEGF bispecific antibody (code: SSGJ-707) and commercialization rights in China [1] - CMB International anticipates that the pharmaceutical industry will experience valuation recovery in 2025, driven by factors such as innovative drug exports, optimization of domestic procurement policies, and the implementation of innovative drug insurance catalog [1] Group 2 - The latest scale of the Hong Kong Stock Connect Technology ETF reached 1.89 billion yuan [2] - Over the past 18 trading days, the ETF has attracted a total of 385 million yuan in inflows [2] - The ETF closely tracks the CSI Hong Kong Stock Connect Technology RMB Index, which selects 50 large-cap, high R&D investment, and high revenue growth technology leading companies from the Hong Kong Stock Connect universe [1]

Group 1: Silicon Manganese - The production of silicon manganese is decreasing, with reductions expanding in Inner Mongolia and Chongqing, leading to a significant decline in output [1] - The continuous decline in market prices is causing hedging profits to turn into losses, resulting in a decrease in warehouse receipts and effective forecasts [1] - Demand remains strong with high pig iron production and recovering steel mill profits, while low inventory levels persist, indicating resilience in finished product demand [1] - Global manganese ore shipments have decreased, particularly due to a sharp drop in arrivals from South Africa, leading to a reduction in port inventories [1] - Despite the decrease in port inventories, future manganese ore shipments are expected to remain high, putting pressure on port traders due to negative profit margins [1] - Short-term expectations indicate that silicon manganese prices will continue to fluctuate and stabilize, with support strengthening as warehouse receipts decrease [1] Group 2: Silicon Iron - Recent environmental inspections in Inner Mongolia are expected to lead to a reduction in daily production by approximately 800 tons from major producers [2] - Overall, silicon iron daily production has decreased, alleviating supply pressure, although inventory levels remain at a medium to high level [2] - Demand for iron remains high, with steel mill profits recovering and resilient demand for finished products, while non-steel demand for magnesium metal is limited due to cautious purchasing [2] - The cost side shows stable prices for raw materials like Lantan, with limited supply-demand conflicts [2] - Future expectations suggest that the supply-demand imbalance for silicon iron is easing, with potential price stabilization and rebound driven by valuation recovery and macroeconomic factors [2]

Group 1 - The core conclusion of the report suggests that recent changes in public fund regulations have increased investor attention on banks and non-bank financial institutions, drawing parallels to the significant market rally in the second half of 2014, which was driven by low allocations and regulatory changes [2][10] - Similarities between the current situation and 2014 include significant underweighting of public funds in financial sectors due to previous bear markets and GDP declines, as well as new regulatory changes, with the 2014 launch of the Shanghai-Hong Kong Stock Connect and the 2025 public fund regulations [10][11] - The report indicates that the banking sector was more undervalued in 2014, with substantial inflows of retail funds expected in the latter half of the year, which is a critical factor for a potential market rally [10][11] Group 2 - The report identifies three main reasons for the financial sector's rally in Q4 2014: (1) public funds were significantly underweight in financials, (2) the launch of the Shanghai-Hong Kong Stock Connect and interest rate cuts by the central bank, and (3) valuation recovery potential based on PB-ROE metrics [3][12][17] - The analysis of PB-ROE metrics shows that in 2014, banks' PB declined faster than ROE due to investor concerns about profitability, leading to a significant valuation recovery in the second half of the year, a pattern that may repeat in 2024 due to current investor fears regarding real estate risks [17][18] - The report notes that the brokerage sector may be experiencing a short-term rotation, with historical patterns indicating that brokerages often perform well at the end of market rallies or during rapid market upswings [19][20] Group 3 - The report anticipates that the A-share market may experience a slight pullback from late May to July, driven by policy expectations and tariff impacts, but expects a return to a bullish market state in Q4 [22][24] - The report emphasizes a preference for value-oriented investments in the current quarter, with a focus on sectors such as banking, real estate, and military industry, while also highlighting the potential of new consumption trends [26][28] - The report suggests that the financial sector remains undervalued, with regulatory encouragement for ETF development and long-term capital inflows likely benefiting banks and related sectors [29]

Core Viewpoint - The metal industry is expected to see steady profit growth in 2024 and the first quarter of 2025, with gold, nickel, cobalt, tin, antimony, rare earth magnetic materials, and copper leading the sectors, while battery metals face pressure at the bottom [1] Group 1: Market Performance - The metal industry has significantly outperformed the market since the beginning of 2025, with the gold sector leading the gains [1] - The non-ferrous metal index increased by 7.7% in 2024 and 6.9% in the first quarter of 2025, outperforming the CSI 300 index by 8.5 percentage points and 8.2 percentage points respectively [1] - In 2024, other rare metals, gold, and aluminum sectors rose by 33.6%, 19.0%, and 17.5% respectively; in 2025, gold, nickel, cobalt, tin, antimony, rare earths, and copper sectors increased by 29.5%, 12.4%, 9.0%, and 8.9% respectively [1] Group 2: Performance and Valuation Analysis - The non-ferrous metal industry achieved a revenue growth of 5.7% year-on-year in 2024, marking six consecutive years of positive growth, with net profit attributable to shareholders increasing by 3.0% [2] - In the first quarter of 2025, the sector's revenue and net profit attributable to shareholders grew by 8.0% and 65.1% year-on-year, indicating a significant acceleration in growth [2] - The expected price-to-earnings (PE) ratio for the non-ferrous metal sector in 2025 is 13.3 times, significantly lower than the industry average of 19.4 times, with rolling PE at 15.9 times and price-to-book (PB) ratio at 2.8 times [2] Group 3: Holdings and Dividend Analysis - As of the end of the first quarter of 2025, the market value of fund holdings in the non-ferrous metal sector was 124.7 billion yuan, ranking 9th among 30 industries [3] - The overall dividend payout ratio for the non-ferrous metal industry reached 35.3% in 2024, up from 34.1% in 2023, with an industry dividend yield of 2.14%, slightly higher than 2.08% in 2023 [3] - Some individual stocks in the sector have dividend yields exceeding 5%, indicating a continuous improvement in shareholder return capabilities [3]

Core Insights - Guizhou Moutai has been in the spotlight recently due to various developments, including the appointment of Zhang Yixing as its cultural tourism ambassador and adjustments to its shareholder meeting venue due to high attendance [1][2][3] Financial Performance - In 2024, Guizhou Moutai reported a total revenue of 1741.44 billion yuan, representing a year-on-year growth of 15.66%, and a net profit of 862.28 billion yuan, with a growth of 15.38% [4] - For Q1 2025, the company achieved a revenue of 506.01 billion yuan, up 10.54% year-on-year, and a net profit of 268.47 billion yuan, increasing by 11.56% [4] - The company has set a revenue growth target of approximately 9% for 2025, estimating an incremental revenue of about 156.7 billion yuan based on 2024 figures [4] Market Reaction - Following the announcement of Zhang Yixing as the brand ambassador, Guizhou Moutai's stock price saw a slight increase, closing at 1555 yuan per share, with a total market capitalization reaching 1.95 trillion yuan [3] - Despite a minor decline in stock price to 1632.01 yuan per share, the company's market capitalization has surpassed 2 trillion yuan again, reaching 2.05 trillion yuan [4][5] Industry Context - The white liquor sector is experiencing a recovery, with major brands like Wuliangye and Luzhou Laojiao also seeing significant price increases [6] - Analysts suggest that the worst phase for the industry has passed, and companies are expected to maintain rational growth targets moving forward [6]